Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,011 across all filing types
Latest filing 2023-06-13 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
关于公司股东股份减持计划时间过半的进展公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the progress of a shareholder's planned reduction of shares (shareholder's shareholding reduction plan progress announcement). It references regulatory requirements for disclosure of shareholding reductions and states that the reduction plan has not yet been implemented. The content focuses on shareholding changes and compliance with disclosure rules, without financial statements or earnings data. This fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels or related shareholder shareholding plans.
2023-06-13 Chinese
关于召开2022年度股东大会通知的公告
AGM Information Classification · 100% confidence The document is a detailed announcement regarding the convening of the 2022 Annual General Meeting (AGM) of 康芝药业股份有限公司. It includes information about the meeting date, location, agenda items to be voted on, voting procedures (both in-person and online), registration details, and proxy forms. The document does not contain financial statements or detailed financial performance data but rather serves as a notice and procedural guide for shareholders to participate in the AGM. The presence of agenda items such as the 2022 annual report and financial statements to be reviewed at the meeting confirms it is an AGM notice. The document length is about 6,034 characters, which is consistent with a detailed meeting notice rather than a full annual report or other financial filing. Therefore, this document fits the category of AGM Information (AGM-R).
2023-06-09 Chinese
康芝药业2023年限制性股票激励计划（草案）摘要
Capital/Financing Update Classification · 95% confidence The document is a detailed draft summary of a 2023 restricted stock incentive plan by 康芝药业股份有限公司 (Kangzhi Pharmaceutical Co., Ltd.). It includes extensive information about the stock incentive plan's purpose, legal basis, management, scope, stock quantity, allocation, vesting conditions, pricing, accounting treatment, and procedures for adjustments and terminations. The document is lengthy (15,000 characters) and contains substantive content about the company's equity incentive plan, including financial and legal details. It is not a brief announcement or a simple notification but a comprehensive plan document. This type of document fits the category of a Capital/Financing Update (CAP), as it relates to company fundraising and capital structure changes through stock incentives. It is not an Annual Report, Earnings Release, or Regulatory Filing. Therefore, the appropriate classification is CAP with high confidence.
2023-06-09 Chinese
康芝药业2023年限制性股票激励计划实施考核管理办法
Board/Management Information Classification · 90% confidence The document is titled as the '2023 Restricted Stock Incentive Plan Implementation Assessment Management Measures' for 康芝药业股份有限公司. It details the governance, assessment criteria, and procedures related to a restricted stock incentive plan, including performance evaluation metrics and management responsibilities. The content focuses on the company's internal governance and management of an equity incentive plan rather than financial results, audit opinions, or shareholder meeting materials. It is not an announcement of voting results, a financial report, or a regulatory filing. The document is a governance-related policy document concerning executive and employee incentives, which fits best under Board/Management Information (MANG) as it relates to management incentives and governance mechanisms. The document length is 2246 characters, which is relatively short but contains substantive policy content rather than a mere announcement or certification, so it is not RNS or RPA.
2023-06-09 Chinese
2023年限制性股票激励计划自查表
Governance Information Classification · 95% confidence The document is a detailed compliance self-inspection checklist related to a 2023 restricted stock incentive plan for 康芝药业股份有限公司. It includes numerous compliance checks, legal and regulatory adherence confirmations, and internal governance procedures related to the stock incentive plan. There is no indication that this is a full financial report, audit report, or earnings release. It is not a brief announcement or a presentation but a compliance and governance-related document focused on stock incentive plans. This fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices, including stock incentive plans and related compliance.
2023-06-09 Chinese
上海荣正企业咨询服务（集团）股份有限公司关于康芝药业股份有限公司2023年限制性股票激励计划（草案）之独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is an Independent Financial Advisor Report related to a 2023 restricted stock incentive plan (股权激励计划) for 康芝药业股份有限公司. It contains detailed analysis and opinions on the stock incentive plan's compliance with laws and regulations, feasibility, scope of incentive recipients, pricing, conditions, and financial impact. The document is lengthy (over 14,000 characters) and includes detailed financial and legal analysis, not just an announcement or summary. It is not an annual or quarterly report, nor an earnings release or management discussion. It is a specialized advisory report on a capital market transaction related to stock incentives. This fits best under the category of Capital/Financing Update (CAP), as it deals with a financing-related equity incentive plan and its independent financial advisor's report. Therefore, the filing type code is CAP with high confidence.
2023-06-09 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.